Pipeline

A robust and nimble engine

We are leveraging our fundamental expertise in immunology and tumor biology to innovate and discover robust and safe TCRs directed against oncogenic and viral driver mutations.

Target

Discovery

IND Enabling

Clinical

Oncogenic Driver Programs

KRAS G12V

KRAS G12D

Mutant P53

Undisclosed

Viral Driver Programs

MCPyV

Undisclosed